Abstract
Migraine is characterized by attacks of intense pulsatile and throbbing headache, typically unilateral in nature with or without aura. Migraine affects a substantial fraction (10-20 %) of the world population (more women than men). With regard to the pathophysiology of migraine, several theories have been proposed; the major three are vascular (due to cerebral vasodilatation), neurological (abnormal neurological firing) and neurogenic dural inflammation (release of inflammatory neuropeptides). The drugs used to treat migraine can be divided into two groups: agents that abolish the acute migraine headache and agents aimed at prevention. The acutely acting antimigraine agents (5-HT1B/1D receptor agonists) stimulated research interest in the field of migraine. Currently prophylactic treatments for migraine include calcium channel blockers, 5-HT2 receptor antagonists, beta-adrenoceptor blockers and γ-amino butyric acid (GABA) agonists. Unfortunately, many of these treatments are non-specific and not always effective. Despite progress, the complex etiology of migraine requires further research, the condition often remains undiagnosed and available therapies are underused. In this review, the evidence that linked the different theories of migraine with its pathophysiology is considered. Furthermore, the present therapeutic targets and future approaches for the acute and prophylactic treatment of migraine are critically evaluated.
Keywords: Migraine, headache, serotonin, vasodilatation
Current Vascular Pharmacology
Title: Migraine: Current Therapeutic Targets and Future Avenues
Volume: 4 Issue: 2
Author(s): D. K. Arulmozhi, A. Veeranjaneyulu and S. L. Bodhankar
Affiliation:
Keywords: Migraine, headache, serotonin, vasodilatation
Abstract: Migraine is characterized by attacks of intense pulsatile and throbbing headache, typically unilateral in nature with or without aura. Migraine affects a substantial fraction (10-20 %) of the world population (more women than men). With regard to the pathophysiology of migraine, several theories have been proposed; the major three are vascular (due to cerebral vasodilatation), neurological (abnormal neurological firing) and neurogenic dural inflammation (release of inflammatory neuropeptides). The drugs used to treat migraine can be divided into two groups: agents that abolish the acute migraine headache and agents aimed at prevention. The acutely acting antimigraine agents (5-HT1B/1D receptor agonists) stimulated research interest in the field of migraine. Currently prophylactic treatments for migraine include calcium channel blockers, 5-HT2 receptor antagonists, beta-adrenoceptor blockers and γ-amino butyric acid (GABA) agonists. Unfortunately, many of these treatments are non-specific and not always effective. Despite progress, the complex etiology of migraine requires further research, the condition often remains undiagnosed and available therapies are underused. In this review, the evidence that linked the different theories of migraine with its pathophysiology is considered. Furthermore, the present therapeutic targets and future approaches for the acute and prophylactic treatment of migraine are critically evaluated.
Export Options
About this article
Cite this article as:
Arulmozhi K. D., Veeranjaneyulu A. and Bodhankar L. S., Migraine: Current Therapeutic Targets and Future Avenues, Current Vascular Pharmacology 2006; 4 (2) . https://dx.doi.org/10.2174/157016106776359853
DOI https://dx.doi.org/10.2174/157016106776359853 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Allosteric Enhancers of A1 Adenosine Receptors: State of the Art and New Horizons for Drug Development
Current Medicinal Chemistry Synergistic Effects of Social Isolation and Morphine Addiction on Reduced Neurogenesis and BDNF Levels and the Resultant Deficits in Cognition and Emotional State in Male Rats
Current Molecular Pharmacology Metabotropic Glutamate Receptors: A Review on Prospectives and Therapeutic Aspects
Mini-Reviews in Medicinal Chemistry Cholinesterases: Roles in the Brain During Health and Disease
Current Alzheimer Research Taking Advantage of Plant Defense Mechanisms to Promote Human Health. The Plant Immune System. First of Two Parts
Endocrine, Metabolic & Immune Disorders - Drug Targets The Pivotal Role of Multimodality Reporter Sensors in Drug Discovery: From Cell based Assays to Real Time Molecular Imaging
Current Pharmaceutical Biotechnology Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry Longitudinal Association between White Matter Hyperintensities and White Matter Beta-Amyloid Deposition in Cognitively Unimpaired Elderly
Current Alzheimer Research Hydrogel Based Drug Delivery Systems: A Review with Special Emphasis on Challenges Associated with Decontamination of Hydrogels and Biomaterials
Current Drug Delivery Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Current Signal Transduction Therapy Imaging Amyloid Pathology in the Living Brain
Current Medical Imaging Development ofNovel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions
Endocrine, Metabolic & Immune Disorders - Drug Targets Fatal Disseminated Toxoplasmosis During Primary HIV Infection
Current HIV Research FDA-approved Drugs Selected Using Virtual Screening Bind Specifically to G-quadruplex DNA
Current Pharmaceutical Design Vitamin D and N-Acetyl Cysteine Supplementation in Treatment-Resistant Depressive Disorder Patients: A General Review
Current Pharmaceutical Design In Silico Modeling of P450 Substrates, Inhibitors, Activators, and Inducers
Combinatorial Chemistry & High Throughput Screening Measuring Morphological and Cellular Changes in Alzheimers Dementia: A Review Emphasizing Stereology
Current Alzheimer Research Chronic Migraineurs Form Carboxyhemefibrinogen and Iron-Bound Fibrinogen
CNS & Neurological Disorders - Drug Targets Imaging of Muscarinic Receptors in the Central Nervous System
Current Pharmaceutical Design Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study (Supplementry Table)
Current Pharmacogenomics and Personalized Medicine